Short Interest in Bionomics Limited (NASDAQ:BNOX) Grows By 1,279.0%

Bionomics Limited (NASDAQ:BNOX) was the target of a large growth in short interest during the month of October. As of October 31st, there was short interest totalling 190,300 shares, a growth of 1,279.0% from the October 15th total of 13,800 shares. Based on an average daily trading volume, of 9,160,000 shares, the days-to-cover ratio is currently 0.0 days.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and set a $8.00 price objective on shares of Bionomics in a research note on Thursday, August 1st.

Bionomics Trading Down 8.9 %

Bionomics stock traded down $0.03 during midday trading on Tuesday, reaching $0.34. 1,414,897 shares of the stock traded hands, compared to its average volume of 3,089,015. Bionomics has a fifty-two week low of $0.18 and a fifty-two week high of $2.19. The firm has a fifty day moving average price of $0.42 and a two-hundred day moving average price of $0.65.

Institutional Investors Weigh In On Bionomics

A hedge fund recently bought a new stake in Bionomics stock. Armistice Capital LLC acquired a new stake in Bionomics Limited (NASDAQ:BNOX) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 1,226,759 shares of the company’s stock, valued at approximately $941,000. Armistice Capital LLC owned approximately 15.03% of Bionomics at the end of the most recent reporting period. 15.90% of the stock is currently owned by institutional investors.

About Bionomics

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder.